dc.creatorOtero losada, Matilde Estela
dc.creatorWandosell, Francisco G.
dc.creatorCapani, Francisco
dc.date.accessioned2022-08-18T18:11:04Z
dc.date.accessioned2022-10-15T08:16:03Z
dc.date.available2022-08-18T18:11:04Z
dc.date.available2022-10-15T08:16:03Z
dc.date.created2022-08-18T18:11:04Z
dc.date.issued2021-06
dc.identifierOtero losada, Matilde Estela; Wandosell, Francisco G.; Capani, Francisco; Neuroprotection in Synaptic Signalling During Neurological Disorders; Frontiers Media; Frontiers in synaptic neuroscience; 13; 746487; 6-2021; 1-3
dc.identifier1663-3563
dc.identifierhttp://hdl.handle.net/11336/166054
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4364054
dc.description.abstractSome of the most devastating and costly conditions in the world arise from neurological andneurodegenerative disorders. About one-third of the world's population suffers from neurologicaldiseases, including Parkinson's (PD) and Alzheimer's (AD) diseases, multiple sclerosis, epilepsy, spinal cord injury, and others. Symptoms may show early in childhood or substantially delayedin adolescence or young adulthood. Animal models are powerful tools aiding in understandingneurological pathophysiology towards developing neuroprotective strategies.So far, there are no well-established treatments for brain repair. Hence, neuroprotectionbecomes imperative. Synapses pose major targets for finding new neuroprotective agents.The aimof this topic is to share research addressing neuroprotective strategies for the brain, theirpossible pathways, and the use of pharmacological analogues. Four reviews are about hypoxia. Twochapters address themolecular bases of cognitive impairment in AD. Biochemical and physiologicalaspects of neuroprotective agents focusing on synaptic modifications, neuroprotection followingperinatal asphyxia, and pharmacological- and genetic-targeting strategies for Alzheimer's and Parkinson's diseases are reviewed.
dc.languageeng
dc.publisherFrontiers Media
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnsyn.2021.746487/full
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fnsyn.2021.746487
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNeuroprotection
dc.subjectrats
dc.subjecthipocampo
dc.subjectcns
dc.titleNeuroprotection in Synaptic Signalling During Neurological Disorders
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución